Healthcare / Medical DevicesTokyo
$562.00
-20.00 (-3.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.1B · quality 76.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.7B
P/E
35.7x
↑EV/EBITDA
2.0x
↓ROE
20.2%
↑Gross Margin
73.7%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+27.7%
FCF CAGR
+27.7%
FCF margin
10.6%
FCF / Net income
0.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.01B · net income $1.41B · FCF $1.06B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.01B | $10.01B | $8.68B | $6.51B | $4.80B |
| Net Income | $1.41B | $1.41B | $1.73B | $1.26B | $686.3M |
| EBITDA | $2.10B | $2.10B | $2.42B | $1.77B | $1.10B |
| EPS | 79.02 | 79.02 | 96.50 | 73.07 | 42.96 |
| Gross Margin | 73.7% | 73.7% | 75.5% | 73.5% | 72.8% |
| Operating Margin | 20.2% | 20.2% | 26.5% | 26.6% | 22.0% |
| Net Margin | 14.1% | 14.1% | 19.9% | 19.3% | 14.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.06 | 0.01 | 0.11 |
| Current Ratio | 3.73 | 3.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.06B | $1.06B | $1.77B | $1.11B | $508.5M |
| Returns | |||||
| ROE | 20.2% | 20.2% | 28.6% | 31.2% | 46.2% |
| Valuation | |||||
| P/E | 35.66 | 35.66 | 13.82 | 17.49 | — |
| EV/EBITDA | 2.00 | 2.00 | 7.57 | 10.27 | — |
| P/B | 1.44 | 1.44 | 3.95 | 5.46 | — |
| Growth & Yield | |||||
| Revenue Growth | 15.2% | 15.2% | 33.3% | 35.6% | — |
| EPS Growth | -18.1% | -18.1% | 32.1% | 70.1% | — |
| Dividend Yield | 10.7% | 10.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-14.2%
EPS terminal req.
$49.87
Spread vs growth
-3.9%
5Y implied EPS CAGR
-5.3%
EPS terminal req.
$60.34
Spread vs growth
-12.9%
10Y implied EPS CAGR
2.1%
EPS terminal req.
$97.18
Spread vs growth
-20.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.0%
Start / end P/E
7.5x → 7.1x
EPS bridge
96.50 → 79.02
Residual
+0.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.